共 23 条
- [1] Phase 3 Study of Roxadustat to Treat Anemia in Non-Dialysis-Dependant CKD [J]. KIDNEY INTERNATIONAL REPORTS, 2021, 6 (07): : 1810 - 1828
- [2] Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2020, 31 (07): : 1628 - 1639
- [4] THE IRON BIOLOGY STATUS OF PERITONEAL DIALYSIS PATIENTS MAY BE A RISK FACTOR FOR DEVELOPMENT OF INFECTIOUS PERITONITIS [J]. PERITONEAL DIALYSIS INTERNATIONAL, 2019, 39 (04): : 362 - 374
- [8] Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (04): : 850 - 866
- [9] Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (03): : 737 - 755